Psyence Biomedical (PBM) Accounts Payables (2023 - 2026)

Psyence Biomedical's Accounts Payables history runs 4 years deep, the most recent figure standing at $407714.0 for Q1 2026.

• On a quarterly basis, Accounts Payables rose 55.65% year-over-year to $407714.0 in Q1 2026; TTM through Mar 2026 was $407714.0, a 55.65% increase from a year earlier, with the FY2026 full-year figure at $407714.0, up 55.65% from the prior year.
• Accounts Payables declined to $407714.0 in Q1 2026 per PBM's latest filing, from $644700.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $1007.7 billion in Q3 2023 and bottomed at $261937.0 in Q1 2025.
• The 4-year median for Accounts Payables is $755202.0 (2024), against an average of $144.0 billion.
• Across the five-year window, Accounts Payables sank 100.0% in 2024 and surged 55.65% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $1007.7 billion in 2023, then sank by 100.0% to $858558.0 in 2024, then fell by 24.91% to $644700.0 in 2025, then tumbled by 36.76% to $407714.0 in 2026.
• Per Business Quant, the three latest PBM Accounts Payables figures stand at $407714.0 (Q1 2026), $644700.0 (Q3 2025), and $261937.0 (Q1 2025).